^
    Back
    Association details:
    Biomarker:KRAS mutation
    Cancer:Colorectal Cancer
    Drug:Ibrance (palbociclib) (CDK4 inhibitor, CDK6 inhibitor) +
    Mektovi (binimetinib) (MEK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Binimetinib and Palbociclib Before Surgery for the Treatment of Operable KRAS-Positive Lung, Colorectal, or Pancreatic Cancer

    Excerpt:
    ...- Patients with verified and operable KRAS-positive mutant lung adenocarcinoma, colorectal, or pancreatic cancer...
    Trial ID:
    NCT04870034
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Oncotarget
    Title:

    Efficacy of the combination of MEK and CDK4/6 inhibitors in vitro and in vivo in KRAS mutant colorectal cancer models

    Excerpt:
    We performed in vitro proliferation, colony formation, apoptosis, and senescence assays, and Western blots, on a panel of 11 KRAS mutant CRC cell lines treated with the MEK inhibitor MEK162, the CDK4/6 inhibitor palbociclib, or the combination...Combined inhibition of both MEK and CDK4/6 is effective in preclinical models of KRAS mutant CRC and justifies a planned phase II clinical trial in patients with refractory KRAS-mutant CRC.
    DOI:
    10.18632/oncotarget.9153